[Hormone therapy in prostate cancer: clinical results].
Palliative hormonotherapy is the choice treatment for disseminated prostatic cancer. The response rate oscillates between 80% and 90% and the mean probability of life expectancy exceeds two years with a substantial improvement in life quality. Hormone dependence of prostate cancer depends as a last instance on the existence of cellular clones with different sensitivity. Finally, the serial monitoring with the specific prostatic antigen allows an objectivation of the response and the early detection of the hormone refractory status.
Morote-Robles
J
J
Servicío de Urología, Hospital Vall d'Hebron, Barcelona, España.
D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens; D002999:Clone Cells; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000627:therapeutic use*; D004351:Drug Resistance; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009919:Orchiectomy; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000726:Androgen Antagonists; D000728:Androgens; D007987:Gonadotropin-Releasing Hormone; D004054:Diethylstilbestrol
Hormonoterapia en el cáncer de próstata: resultados clínicos.